Implantable cardioverter-defibrillator therapy in clinical practice

Journal of the American College of Cardiology
David A Cesario, G William Dec

Abstract

Pharmacologic treatment of heart failure has led to dramatic improvements in survival and quality of life. Nonetheless, heart failure often progresses despite treatment with diuretics, angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, aldosterone antagonists, and digoxin. Further, despite a steady decline in the risk of death from pump failure, many patients remain at high risk for sudden cardiac death. The annual incidence of sudden cardiac death in the U.S. alone has been estimated at 184,000 to over 400,000 cases. During the past decade, substantial advances have been made in the use of device-based therapy for this population. The role of the implantable cardioverter-defibrillator (ICD) continues to evolve in routine heart failure management. The current status of ICD therapy in the treatment of heart failure patients based on randomized clinical trial results and published practice guidelines is summarized in this review.

References

Sep 17, 1992·The New England Journal of Medicine·G M VincentM Keating
Jan 21, 1988·The New England Journal of Medicine·G ThieneN Pennelli
Aug 11, 1983·The New England Journal of Medicine·UNKNOWN Multicenter Postinfarction Research Group
Feb 1, 1982·Circulation·F I MarcusY Grosgogeat
Dec 1, 1995·Journal of the American College of Cardiology·W ZarebaM L Andrews
Mar 1, 1995·The American Journal of Cardiology·A P HallstromUNKNOWN AVID Investigators
Nov 26, 1993·The American Journal of Cardiology·J SiebelsK H Kuck
Aug 1, 1993·Circulation·P J SchwartzR S Crampton
Jun 1, 1996·Circulation·L G Escobedo, M M Zack
Dec 31, 1997·The New England Journal of Medicine·UNKNOWN Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators
Jun 11, 1999·Journal of the American College of Cardiology·B P KnightS A Strickberger
Feb 10, 2000·The New England Journal of Medicine·H Watkins
Jun 15, 2000·The New England Journal of Medicine·P SpiritoB J Maron
Aug 10, 2000·Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·C Basso
Aug 11, 2000·European Journal of Heart Failure·M KomajdaF Tesson
Sep 19, 2000·Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·P Della Bella
Dec 29, 2000·Journal of the American College of Cardiology·A NavaG Thiene
Mar 22, 2001·The New England Journal of Medicine·S CazeauUNKNOWN Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators
Oct 5, 2001·Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·J A Salerno-Uriarte, M Tritto
Oct 31, 2001·Circulation·Z J ZhengG A Mensah
Jan 17, 2002·The New England Journal of Medicine·H V HuikuriR J Myerburg
Mar 22, 2002·The New England Journal of Medicine·Arthur J MossUNKNOWN Multicenter Automatic Defibrillator Implantation Trial II Investigators
May 30, 2002·European Journal of Heart Failure·Daniel GrasAnders Kirstein-Pedersen
Jun 14, 2002·The New England Journal of Medicine·William T AbrahamUNKNOWN MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation
Jul 26, 2002·Journal of Cardiovascular Electrophysiology·Robert J Myerburg
Dec 17, 2002·JAMA : the Journal of the American Medical Association·Leonard A CobbMichael K Copass
May 14, 2003·Journal of the American College of Cardiology·Douglas S LeeDavid A Alter

❮ Previous
Next ❯

Citations

Jan 13, 2009·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Alessandro ProclemerMichele Brignole
Sep 21, 2010·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Alpay ÇelikerDursun Alehan
May 29, 2010·Journal of Cardiovascular Pharmacology·Mithilesh K Das, Douglas P Zipes
May 12, 2007·International Journal of Clinical Practice·Nicholas P Gall
Sep 1, 2007·Current Treatment Options in Cardiovascular Medicine·Martin CadeirasMario C Deng
Sep 20, 2007·Current Cardiology Reports·Mithilesh K DasJohn M Miller
Dec 8, 2007·Cardiology Clinics·David A CesarioG William Dec
Dec 12, 2007·Pacing and Clinical Electrophysiology : PACE·Michael ReinigLawrence Gessman
Mar 25, 2008·Pacing and Clinical Electrophysiology : PACE·Nico A Blom
Apr 4, 2008·Journal of Cardiovascular Electrophysiology·Barry J Maron, Paolo Spirito
Jun 18, 2010·Cardiovascular Therapeutics·Rose Do, Kristen K Patton
May 18, 2012·The Cochrane Database of Systematic Reviews·Mohammed QintarWaleed Kadro
Jun 13, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Arpad Tosaki, Istvan Edes
Feb 13, 2009·Expert Review of Cardiovascular Therapy·Mithilesh Das
Dec 5, 2006·Current Opinion in Cardiology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Arrhythmogenic Right Ventricular Dysplasia

Arrhythmogenic right ventricular dysplasia is a congenital cardiomyopathy that is characterized by infiltration of adipose and fibrous tissue into the right ventricle wall and loss of myocardial cells. Primary injuries usually are at the free wall of the right ventricular and right atria resulting in ventricular and supraventricular arrhythmias. Discover the latest research on arrhythmogenic right ventricular dysplasia here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.